Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.

Autor: Yan X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Ning ZY; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Wang P; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Zhuang LP; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Xu LT; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Zhu ZF; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Sheng J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Shen YH; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Hua YQ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China., Meng ZQ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Cancer minimally invasive treatment center, Fudan University Shanghai Cancer Center, Shanghai, China.
Jazyk: angličtina
Zdroj: Expert review of gastroenterology & hepatology [Expert Rev Gastroenterol Hepatol] 2021 Sep; Vol. 15 (9), pp. 1047-1056. Date of Electronic Publication: 2021 Jan 08.
DOI: 10.1080/17474124.2021.1869937
Abstrakt: Objectives : To retrospectively assess the efficacy of combined ablation-chemotherapy in comparison to that of chemotherapy alone in patients with liver metastasized pancreatic ductal adenocarcinoma (lmPDAC). Methods : In total 104 patients with hepatic oligo metastasized PDAC were identified; among them, 74 patients underwent combined thermal ablation-chemotherapy, and 30 patients underwent chemotherapy alone. Through propensity score matching, 1:1 matching of the combined ablation-chemotherapy group and chemotherapy group was achieved. The primary endpoint of this study was overall survival (OS). Clinical and tumor-related factors affecting OS were also analyzed through univariate and multivariate analyses using the Cox risk model. Results : For patients treated with combined ablation-chemotherapy, the median OS was 10.77 months, while it was 5.77 months for patients treated with chemotherapy alone (P = 0.011). The survival benefit for patients treated with combined ablation-chemotherapy was still preserved in the matched cohort, with a median OS of 8.17 months compared to 5.77 months in the chemotherapy group. Univariate and multivariate analyses in the matched population also showed treatment with combined ablation-chemotherapy was an independent prognostic factor (P < 0.05). Conclusions : For patients with liver metastases from pancreatic cancer, the combined use of thermal ablation and systemic chemotherapy offers a chance for a better survival outcome.
Databáze: MEDLINE
Externí odkaz: